A phase IIb open label, randomized clinical trial evaluating efficacy and safety of Myrcludex B in combination with tenofovir in patients with chronic hepatitis B and D co-infections

Trial Profile

A phase IIb open label, randomized clinical trial evaluating efficacy and safety of Myrcludex B in combination with tenofovir in patients with chronic hepatitis B and D co-infections

Completed
Phase of Trial: Phase II

Latest Information Update: 27 Mar 2018

At a glance

  • Drugs Myrcludex-B (Primary) ; Tenofovir
  • Indications Hepatitis B; Hepatitis D
  • Focus Therapeutic Use
  • Most Recent Events

    • 27 Mar 2018 According to a MYR Pharma media release, data from this trial will be presented at the upcoming International Liver Congress organized by the European Association for the Study of the Liver (EASL) 2018.
    • 12 Mar 2018 According to MYR Pharma media release, Status changed from active, no longer recruiting to completed.
    • 12 Mar 2018 According to MYR Pharma media release, positive results of the active therapy phase of this study were already presented at the AASLD meeting in Washington
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top